纵横研报
Ticker Detail

SNN.US

$30.93+3.69% 施乐辉公司 Medical Devices
00Reports USA 医疗健康
Smith & Nephew SNATS Inc
医疗健康 · 医疗器械

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

MARKET 市值 12.94B USD PE 21.5x Fwd 13.3x 52W $28.56 – $37.9 EODHD · Q 2025-12-31 · 同步 2026-07-12
QUALITY PEG 1.18 营收 YoY 7.4% ROE 11.8% 营业利润率 14.0% 净利润率 10.1%
ANALYST 一致评级 3.75 一致目标价 $34.07 +10.2% 股息率 2.55%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制